Summit Securities Group’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
Other funds holding RYTM
Summit Securities Group's RYTM Position: Q3 2026 in Review
Summit Securities Group sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2026, closing a stake of 543 shares — an estimated $60.3K sold.
Summit Securities Group first reported a position in RYTM in Q2 2026 and held it in 1 quarter. The position peaked at $60.3K in Q2 2026. 239 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.
- Summit Securities Group reported no remaining Rhythm Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Summit Securities Group sold 543 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $60.3K.
- Summit Securities Group first reported a position in Rhythm Pharmaceuticals in Q2 2026 and held it in 1 quarter.
- Summit Securities Group's Rhythm Pharmaceuticals position peaked at $60.3K in Q2 2026.
- 239 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.
Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.